Last updated: August 20, 2026
Malarone Pediatric is the pediatric-strength formulation of atovaquone/proguanil hydrochloride used for malaria prophylaxis and treatment. Its commercial trajectory is mature: the original brand has lost meaningful patent exclusivity, generic atovaquone/proguanil products compete on price, and GSK does not disclose standalone Malarone Pediatric revenue. Current value is concentrated in brand recognition, physician familiarity, travel-clinic distribution, and supply reliability rather than in patent protection.
What is Malarone Pediatric and how is it used?
Malarone Pediatric contains 62.5 mg atovaquone and 25 mg proguanil hydrochloride per tablet. It is indicated for prevention of Plasmodium falciparum malaria and for treatment of uncomplicated malaria in adults and children weighing at least 5 kg, subject to labeling restrictions and medical guidance. Pediatric dosing is weight-based, with tablets taken daily for prophylaxis and for a short treatment course in malaria cases.[1]
| Attribute |
Malarone Pediatric |
| Active ingredients |
Atovaquone and proguanil hydrochloride |
| Pediatric strength |
62.5 mg/25 mg per tablet |
| Adult strength |
250 mg/100 mg per tablet |
| Primary use |
Malaria prophylaxis and treatment |
| Product type |
Small-molecule prescription drug |
| Originator |
GlaxoSmithKline |
| Principal commercial channel |
Travel medicine, retail pharmacy, infectious-disease care |
| FDA pathway |
New drug application for fixed-dose combination |
| Biosimilar exposure |
None |
| Generic exposure |
High |
The product is taken with food or a milky drink to improve atovaquone absorption. It is not generally used for severe malaria, and it is not the preferred option for every destination or patient group. Destination-specific resistance, pregnancy, renal status, age, weight, and local treatment guidelines affect prescribing decisions.[1,2]
What patents protect Malarone Pediatric?
Malarone Pediatric is no longer protected by a commercially meaningful period of U.S. exclusivity. The core atovaquone/proguanil combination patents expired years ago, and generic manufacturers have entered the U.S. market.
The key commercial distinction is between the active pharmaceutical ingredient combination and the pediatric presentation. The pediatric tablet does not create a separate long-term monopoly over the underlying combination. A manufacturer may obtain protection for a particular formulation, manufacturing process, packaging configuration, or dosing method, but those rights do not generally prevent generic products containing the same active ingredients from competing.
| IP category |
Commercial relevance |
| Atovaquone composition patents |
Expired or no longer effective against current generic competition |
| Proguanil composition patents |
Expired |
| Fixed-dose combination patents |
Expired or commercially exhausted in major markets |
| Pediatric tablet strength |
Does not independently create broad exclusivity |
| Method-of-use patents |
Limited practical value where prophylaxis and treatment uses are established |
| Manufacturing patents |
Potentially relevant to cost and supply, but not a broad market barrier |
| Trademark rights |
Brand protection remains, but does not block generic substitution |
The FDA Orange Book remains the primary source for current patent and exclusivity listings. A current listing must be reviewed before making a litigation or launch determination because patent records, delistings, and product-specific entries can change.[3]
When did Malarone Pediatric lose exclusivity?
Malarone Pediatric lost the commercial advantages associated with new-drug and formulation exclusivity before the current generic market matured. The product’s competitive position shifted from protected innovation to a branded legacy product.
The relevant sequence was:
- GSK commercialized the atovaquone/proguanil combination for malaria prevention and treatment.
- Regulatory exclusivity and core patent rights expired.
- Generic manufacturers introduced atovaquone/proguanil tablets in adult and pediatric-equivalent strengths.
- Pharmacy substitution and payer price controls reduced the brand’s ability to maintain premium pricing.
- Malarone retained demand among patients and clinicians who prefer the original brand or encounter supply differences between manufacturers.
No current patent expiry date should be treated as a future loss-of-exclusivity catalyst comparable to a protected blockbuster. The main loss-of-exclusivity event has already occurred.
What is the FDA and Orange Book status of Malarone Pediatric?
Malarone Pediatric is an FDA-approved prescription product. Its regulatory value comes from the established approval, labeling, and clinical history rather than from active market exclusivity.
The FDA-approved label identifies the pediatric tablet as a lower-strength version of the fixed-dose atovaquone/proguanil combination. Generic manufacturers can rely on the reference product’s established safety and efficacy through abbreviated new drug applications, provided their products meet applicable pharmaceutical equivalence and bioequivalence standards.[1,4]
Regulatory factors affecting demand
Several label-related factors influence the product’s addressable market:
- Pediatric use is weight-dependent.
- Children below the minimum labeled weight are outside the standard indicated population.
- Atovaquone absorption depends on administration with food or a milky drink.
- Severe malaria requires alternative clinical management.
- Drug interactions can affect treatment selection.
- Proguanil-containing products have restrictions or cautions in specific patient populations.
The pediatric market is therefore narrower than the total malaria-prophylaxis market. Prescribers select among atovaquone/proguanil, doxycycline, and mefloquine based on destination, age, pregnancy status, adverse-effect concerns, adherence, and resistance patterns.[2]
How strong is the Malarone Pediatric patent estate?
The current patent estate is weak as a barrier to generic entry. The product has several commercial strengths, but active exclusivity is not one of them.
Patent-strength assessment
| Factor |
Assessment |
Commercial effect |
| Core composition protection |
Weak or expired |
Does not prevent generic entry |
| Pediatric formulation protection |
Limited |
May affect a specific product design but not the active combination broadly |
| Method-of-use protection |
Limited |
Malaria prophylaxis and treatment uses are established |
| Manufacturing know-how |
Moderate |
Can influence cost, quality, and supply continuity |
| Brand recognition |
Moderate |
Supports residual demand and travel-clinic preference |
| Regulatory history |
Strong |
Supports physician confidence and generic referencing |
| Litigation leverage |
Low |
Limited basis for blocking routine generic competition |
The greatest remaining IP value may lie in manufacturing controls, quality systems, supplier relationships, and regulatory documentation. These factors can create operational barriers without creating enforceable market exclusivity.
Which companies are challenging Malarone Pediatric?
The relevant challengers are generic pharmaceutical manufacturers, not biosimilar developers. Atovaquone/proguanil is a small-molecule combination and is therefore subject to the generic drug pathway rather than the biosimilar pathway.
Generic competition has included products marketed under the names atovaquone and proguanil hydrochloride, with manufacturers entering through abbreviated new drug applications. The competitive set can change as approvals, suppliers, and distributors change.
Typical generic competitors compete through:
- Lower acquisition cost
- Retail pharmacy substitution
- Medicaid and managed-care formulary placement
- Wholesale distribution
- Contract manufacturing
- Availability in adult and pediatric-equivalent strengths
Because the product is used frequently for short travel courses, patient retention is weaker than in chronic therapies. A patient may choose the lowest-cost product for a single trip rather than remain loyal to the brand.
What generic entry risks exist for Malarone Pediatric?
Generic entry risk is high and ongoing. The principal commercial threat is price erosion, not a single future launch event.
Generic launch scenarios
| Scenario |
Probability |
Effect on brand |
| Continued multi-source generic competition |
High |
Sustained price pressure |
| Temporary generic shortage |
Moderate |
Short-term brand or alternative-product recovery |
| Travel rebound increases category demand |
Moderate |
Volume growth may offset some price erosion |
| New resistance changes prescribing |
Low to moderate |
Could reduce or redirect demand by geography |
| Pediatric-specific supply disruption |
Moderate |
May support temporary brand demand |
| New branded formulation |
Low |
Limited incentive without differentiated clinical value |
The pediatric segment can experience disproportionate supply disruptions because demand is smaller and manufacturers may prioritize higher-volume adult products. That creates occasional opportunities for branded supply, but these are episodic and do not restore durable exclusivity.
What market dynamics drive Malarone Pediatric demand?
Malarone Pediatric demand is tied to international travel, malaria incidence, travel advisories, and access to pediatric travel medicine. It is not primarily driven by chronic disease prevalence.
Key demand drivers
International travel is the strongest volume driver in prophylaxis markets. Demand fell sharply during pandemic-era travel restrictions and recovered as tourism, business travel, humanitarian activity, and military movement resumed. Pediatric demand follows family travel but is smaller than adult demand.
Malaria-endemic destination patterns also matter. Prescribing is higher for travel to areas where atovaquone/proguanil is recommended or preferred and lower where other prophylactic agents are more suitable.
Physician and parent preferences support the product because atovaquone/proguanil has a short post-travel dosing period and is often viewed as easier to complete than longer regimens. The price of the branded product can limit use where insurers impose high co-payments.
Resistance and guideline changes create geographic variation. The Centers for Disease Control and Prevention continues to recommend destination-specific malaria prevention strategies rather than a single universal prophylactic product.[2]
How does Malarone Pediatric compare with competing malaria drugs?
Malarone Pediatric competes with both branded and generic atovaquone/proguanil products, as well as non-equivalent prophylactic drugs.
| Product or class |
Main advantage |
Main limitation |
Commercial position |
| Generic atovaquone/proguanil |
Lower price, same active combination |
Variable availability and manufacturer familiarity |
Primary price competitor |
| Malarone Pediatric |
Brand recognition and established labeling |
Premium price |
Residual branded demand |
| Doxycycline |
Low cost and broad availability |
Daily dosing, photosensitivity, pediatric restrictions |
Strong adult alternative |
| Mefloquine |
Weekly dosing |
Neuropsychiatric and other tolerability concerns |
Destination- and patient-specific use |
| Primaquine or tafenoquine |
Specific clinical utility |
Additional screening or use limitations |
Niche alternative |
Malarone’s commercial advantage is convenience and familiarity. Its weakness is cost. Generic substitution removes much of the economic value of the brand unless a payer, pharmacy, or patient gives priority to the reference product.
What is the financial trajectory of Malarone Pediatric?
GSK does not report standalone global revenue for Malarone Pediatric or, in most public reporting, for the Malarone brand as a separate line item. The product’s financial trajectory must therefore be assessed through lifecycle indicators rather than audited product-level sales.
Financial trajectory by stage
| Period |
Commercial condition |
Financial implication |
| Launch and protected period |
Brand-controlled market |
Higher price and stronger gross margin |
| Early generic transition |
First generic entrants |
Rapid price and share pressure |
| Mature generic market |
Multiple suppliers |
Lower average selling price |
| Pandemic travel contraction |
Reduced international travel |
Significant volume weakness |
| Travel normalization |
Recovery in prophylaxis demand |
Volume improvement without restoring former pricing |
| Current mature stage |
Brand plus generics |
Low-to-moderate residual brand value |
The financial profile is likely characterized by declining branded revenue over the long term, interrupted by travel-cycle recoveries and supply-driven price changes. A rise in prescription volume does not necessarily translate into equivalent revenue growth because generic substitution and payer discounts reduce net price.
Revenue exposure
Malarone Pediatric is unlikely to be material to GSK’s consolidated financial results. GSK’s public reporting emphasizes larger vaccines, specialty medicines, respiratory products, HIV medicines, and other major portfolio categories. Malarone is a legacy anti-infective product rather than a major growth asset.[5]
For investors or licensing parties, the most relevant financial variables are:
- Net sales by country
- Brand-to-generic substitution rate
- Wholesale acquisition cost
- Average rebate and discount rate
- Pediatric versus adult volume
- Travel prescription recovery
- Stock-out frequency
- Manufacturing cost and supplier concentration
- Distribution rights by territory
Without product-level disclosure, any precise revenue estimate would be speculative.
What patent litigation affects Malarone Pediatric?
Malarone Pediatric does not present the profile of an active, high-value Paragraph IV litigation program. The core exclusivity period has expired, and the market is mature.
Paragraph IV risk is still relevant as a legal framework when a generic applicant challenges a listed patent. A generic applicant may certify that a listed patent is invalid, unenforceable, or not infringed. The reference-product sponsor can then file litigation, potentially triggering a statutory stay of FDA approval under the Hatch-Waxman framework.[4]
For Malarone Pediatric, the practical assessment is:
- No major current litigation catalyst is evident from the mature product profile.
- Any new case would require review of current Orange Book listings and court dockets.
- Formulation or manufacturing patents would have narrower scope than a composition patent.
- A settlement would have limited economic value unless it delayed a major competitor or protected a differentiated presentation.
Are there licensing deals involving Malarone Pediatric?
Malarone originated within GSK’s anti-infective portfolio. Publicly disclosed transactions involving the product have not established a major current licensing thesis comparable to products with active co-development, royalty, or regional commercialization rights.
Potential transaction value would be highest in territories where:
- Malaria travel demand is increasing.
- Generic supply is fragmented.
- The brand retains physician recognition.
- Pediatric formulations are difficult to source.
- A local partner has strong travel-clinic distribution.
In major developed markets, the absence of active exclusivity reduces the value of a standalone brand license. A buyer would likely focus on manufacturing economics, regulatory rights, supply continuity, and portfolio bundling.
What generic launch and investment risks exist?
The principal risk is continued erosion of the branded business. Other risks include:
- Generic price competition reduces net revenue.
- Travel demand fluctuates with geopolitics, public-health events, and economic conditions.
- Pediatric volumes are too small to support multiple suppliers in every market.
- Supply interruptions can shift demand temporarily but unpredictably.
- Alternative prophylactic medicines limit pricing power.
- Regulatory or guideline changes can redirect prescribing.
- Country-specific patent and regulatory status may differ from the U.S. position.
The main upside is limited. It would come from travel-market expansion, temporary generic shortages, improved pediatric distribution, or a differentiated delivery format. None is equivalent to a new patent-protected indication.
Key Takeaways
- Malarone Pediatric is the 62.5 mg/25 mg atovaquone/proguanil formulation for pediatric malaria prophylaxis and treatment.
- The product has no meaningful remaining composition-patent barrier to generic competition in the United States.
- Generic entry risk is high, and price erosion is the dominant commercial pressure.
- No biosimilar risk applies because atovaquone/proguanil is a small-molecule drug.
- GSK does not disclose standalone Malarone Pediatric revenue, preventing a verified product-level financial forecast.
- Demand depends heavily on international travel, malaria destination patterns, pediatric access, and supply availability.
- The brand retains value through recognition, labeling history, and supply reliability, not through active exclusivity.
- Litigation and licensing value are limited unless a new formulation, manufacturing right, or regional commercial opportunity emerges.
FAQs
Is Malarone Pediatric still under patent protection?
Core patent protection for atovaquone/proguanil has expired or lost practical exclusivity in major markets. Current Orange Book records should be checked for any product-specific listing.
Can pharmacies substitute generic atovaquone/proguanil for Malarone Pediatric?
Substitution depends on the specific generic strength, state law, payer rules, prescription instructions, and pharmacy practices. The generic must meet FDA approval requirements for the relevant product.
Does Malarone Pediatric have pediatric exclusivity?
Pediatric clinical studies may have supported regulatory benefits during the product’s lifecycle, but any historical pediatric exclusivity does not create a current commercial barrier comparable to an active patent.
What is the biggest commercial threat to Malarone Pediatric?
The biggest threat is sustained generic substitution combined with lower net pricing. Travel-volume changes affect demand, but generic competition determines the long-term branded revenue ceiling.
Could a new pediatric formulation revive the brand?
A new formulation could improve adherence, dosing convenience, or palatability, but commercial success would depend on regulatory differentiation, payer coverage, manufacturing cost, and the ability to avoid rapid generic substitution.
References
- U.S. Food and Drug Administration. (2023). Malarone (atovaquone and proguanil hydrochloride) tablets: Prescribing information.
- Centers for Disease Control and Prevention. (2024). CDC Yellow Book 2024: Health information for international travel, malaria. Oxford University Press.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2024). Generic drug facts and abbreviated new drug applications.
- GSK plc. (2024). Annual report 2023.
